Review On Recent Advances in Nitrogen Heterocycles: Synthesis, Properties, And Emerging Applications

Heterocycles are cyclic organic compounds in which one or more atoms in the ring are heteroatoms—most commonly nitrogen, oxygen, or sulfur—rather than carbon [1-4]. They play a crucial role in medicinal chemistry, materials science, and natural‑product chemistry, as they constitute the core structures of numerous drugs, nucleic acids, dyes, and agrochemicals [1-4]. A heterocyclic compound is defined as any cyclic molecule that contains at least one heteroatom in the ring; common heteroatoms include N, O, S, P, and less frequently Se, Si, etc. Structurally, heterocycles are usually classified by [1,4]:

• Ring size (3‑membered small rings, 5‑ and 6‑membered common, 7‑ and 8‑membered medium/large rings) [1,3].
• Degree of unsaturation (fully saturated, partially saturated, or aromatic) [1,3].
• Nature of heteroatoms (N‑, O‑, S‑containing, or mixed‑heteroatom systems) [1,4].

Nitrogen heterocycles are present in the majority of small‑molecule drugs (over 80% of recent FDA‑approved drugs contain at least one N‑heterocyclic ring) [1,5]. They structurally resemble natural substrates, nucleic acid bases, alkaloids, and enzyme cofactors, which helps in target recognition [6]. Nitrogen atoms act as hydrogen‑bond donors/acceptors and coordinate with metal ions, improving interaction with enzymes, receptors, and nucleic acids [6,7]. N‑heterocycles help tune lipophilicity, solubility, pKa, and metabolic stability, influencing absorption, distribution, and bioavailability [7,8]. Easy substitution and ring fusion on N‑heterocyclic cores allow systematic SAR optimization [7]. It is present in antibiotics, antivirals, anticancer, CNS agents, antihypertensives, and NSAIDs [5]. Many kinase inhibitors and receptor‑selective drugs rely on N‑heterocyclic rings for selectivity [9]. Nitrogen‑containing heterocycles play a central role in modern materials science, where they are key components of organic semiconductors, OLED emitters, dyes, and luminescent/fluorescent probes due to their conjugated π‑systems, tunable electronic structure, and strong absorption–emission characteristics [10]. Numerous nitrogen heterocycles have been incorporated into optoelectronic and energy‑related devices such as dye‑sensitized solar cells, organic photovoltaics, and chemical sensors, where they function as efficient light‑harvesting units, charge‑transport materials, or signal‑transducing fluorophores [11]. In homogeneous catalysis, N‑heterocyclic carbenes and pyridine‑based ligands have emerged as powerful supporting ligands for transition‑metal complexes, offering strong σ‑donation, steric tunability, and enhanced stability, which has led to highly active catalysts for cross‑coupling, C–H functionalization, and other key transformations [12]. These scaffolds further find use in dyes, pigments, cosmetic colorants, food additives, and polymer additives, where their heteroatom‑containing rings enable precise tuning of color, stability, and compatibility with different matrices [6,7]. Taken together, the broad utilization of nitrogen heterocycles in drugs, agrochemicals, electronic materials, catalysts, and specialty chemicals demonstrates that they are truly “privileged scaffolds” in contemporary chemistry, providing a versatile platform for designing functional molecules across multiple industries [13]. This review aims to give a concise, overview of recent advances in nitrogen heterocycles, focusing on their synthesis, important physicochemical properties, and applications in drug molecules and functional materials. It highlights commonly used 5‑ and 6‑membered N‑heterocyclic scaffolds and selected fused systems, and summarizes modern synthetic approaches, structure–property relationships, and emerging roles in medicinal chemistry and materials science.

1. Classification and basic features

Nitrogen heterocycles are cyclic compounds in which one or more ring atoms are nitrogen, and they are broadly classified into 5‑membered, 6‑membered, and fused/polycyclic systems that serve as core scaffolds in numerous drug molecules and functional materials [5]. Common 5‑membered N‑heterocycles include pyrrole (a weakly basic aromatic ring present in many natural products), imidazole (important in histidine and enzyme‑active‑site mimics), pyrazole and triazole (widely used as hydrogen‑bonding pharmacophores in antimicrobial and anticancer agents), and thiazole (containing both nitrogen and sulfur, found in vitamins and antibacterial drugs) [14]. Among 6‑membered N‑heterocycles, pyridine is a strongly basic, electron‑deficient aromatic ring frequently encountered in drug Discovery portfolios, while pyrimidine forms the backbone of nucleic acid bases and nucleoside‑analogue therapeutics [9,15]. Saturated systems such as piperidine and piperazine are non‑aromatic nitrogen heterocycles commonly used to modulate basicity, solubility, and bioavailability in CNS‑acting and other pharmaceuticals [15]. Finally, fused and polycyclic systems such as indole, quinoline, isoquinoline, benzimidazole, and benzothiazole combine benzene with 5‑ or 6‑membered heterocyclic rings and are repeatedly found in antimicrobial, anticancer, and CNS‑active drug candidates [14,16].

5 Membered N containing Heterocyclic Ring     Pyrrole             Pyrazole        Imidazole

6 Membered N containing Heterocyclic Ring       Piperidine                Piperazine             Pyridine               Pyrazine               Pyrimidine

General paal knorr synthesis of pyrroles

Pyrrole synthesis catalyzed by iron

Larock indole synthesis

6. Emerging Applications in Drug discovery and Development

Nitrogen heterocycles play increasingly transformative roles in modern drug discovery and development through several emerging applications [32,33]. One of the most significant advancements is the integration of artificial intelligence (AI) and machine learning in heterocyclic drug design. Machine learning algorithms now predict structure-activity relationships (SAR) for nitrogen heterocycles with remarkable accuracy, enabling identification of novel drug candidates much faster than traditional screening methods [32,33]. AI-driven platforms optimize heterocyclic scaffolds for improved bioavailability, selectivity, and reduced toxicity, while computational tools screen millions of heterocyclic compounds to prioritize candidates for synthesis and testing. This revolutionary approach has reduced drug discovery time from 10–15 years to 5–7 years and cut costs by 30–50%, representing a paradigm shift in pharmaceutical research [32,33].

Fluorinated heterocycles represent another major emerging application, with fluorine incorporation into heterocyclic structures significantly increasing metabolic stability, membrane permeability, and binding affinity [33]. Approximately 35% of FDA-approved drugs contain fluorine, and many are heterocyclic compounds including fluoroquinolones and fluoropyrimidines such as Fluorouracil, Ciprofloxacin, Efavirenz, and Fluconazole [33]. The high electronegativity of fluorine modifies electron distribution in heterocycles, improving drug-target interactions and resulting in enhanced therapeutic efficacy [33].

In targeted therapy and precision medicine, nitrogen heterocycles serve as critical protein kinase inhibitors in cancer treatment [33,34]. Pyrimidines and indoles specifically inhibit protein kinases, making them essential for targeted cancer therapy [33,34]. Over 50% of new anticancer drugs currently in clinical trials contain heterocyclic scaffolds, and these targeted therapies demonstrate higher efficacy and lower toxicity compared to traditional chemotherapy approaches [33,34]. Personalized drug design now tailors heterocyclic scaffolds to patient-specific mutations, with EGFR inhibitors containing quinazoline rings representing successful examples of this approach [33,34].

The application of nanotechnology and drug delivery systems has expanded heterocyclic utility dramatically [33]. Nitrogen heterocycles including pyridines and imidazole are now used in polymeric nanoparticles for targeted drug delivery, significantly enhancing solubility and stability of poorly water-soluble drugs [33]. These nanoparticle-heterocycle conjugates enable controlled release and reduce off-target effects, with emerging applications in cancer-targeted nanoparticles and brain-delivery systems for CNS drugs demonstrating the potential for treating previously inaccessible diseases [33].

Fragment-based drug design (FBDD) utilizes small heterocyclic fragments such as pyrroles and pyridines as starting points for rapid drug candidate assembly [33,35]. Multicomponent reactions combine these heterocyclic fragments to generate thousands of candidates for screening, reducing screening costs and accelerating lead identification [33,35]. Successful drugs including Venafenib (kinase inhibitor) and Bortezomib (anticancer) were designed using FBDD with heterocyclic scaffolds, demonstrating the practical clinical value of this approach [33,35].

Green chemistry and sustainable manufacturing approaches for heterocycle synthesis are gaining regulatory and industrial importance [33,36]. Microwave-assisted, sonochemical, and solvent-free methods reduce waste and energy consumption while enabling robust synthetic routes for bulk production of heterocyclic drugs [33,36]. These sustainable methods cut production costs by 20–30% and improve environmental compliance while aligning with ICH and FDA guidelines for pharmaceutical quality and sustainability [33,36].

Emerging therapeutic areas now include antiviral applications with pyrimidines and purines targeting HIV, Hepatitis B/C, and SARS-CoV-2, antibacterial applications with quinolones and triazoles addressing drug-resistant bacteria like MRSA and E. coli, and neurodegenerative disease treatments using pyridines and indoles for Alzheimer's and Parkinson's [33,34]. Heterocycles are also expanding into immunomodulatory applications for autoimmune diseases and cancer immunotherapy using benzimidazoles and piperazines, demonstrating the expanding scope of nitrogen heterocycles in treating previously unaddressed conditions [33,34].

Neuroprotective agents based on indoles, pyridines, and benzimidazoles show remarkable activity in preventing neuronal death in Alzheimer's and Parkinson's diseases [33]. These compounds inhibit oxidative stress, reduce inflammation, and block excitotoxicity, offering dual action by treating symptoms while slowing disease progression [33]. Several heterocyclic neuroprotectants are currently in Phase II and III clinical trials for neurodegenerative diseases, representing promising future therapeutic options [33].

Antioxidant and cytoprotective applications utilize pyrazoles, pyridines, and imidazole that scavenge free radicals and protect cells from oxidative damage [33]. These heterocycles reduce lipid peroxidation and enhance glutathione levels, making them valuable for treating ischemia and diabetes complications [33]. Their emerging uses in cardiovascular protection and anti-diabetic therapies demonstrate the expanding therapeutic potential of nitrogen heterocycles beyond traditional applications [33].

Overall, nitrogen heterocycles continue to drive innovation across multiple therapeutic areas through these emerging applications, with AI-driven design, fluorination strategies, targeted delivery, and sustainable manufacturing approaches representing the future of heterocyclic drug development in modern pharmaceutical science [33].

7. Challenges in Pharmaceutical Synthesis and Formulation

7.1. Poor Solubility & Low Bioavailability

Poor aqueous solubility is a common problem in new drug candidates, affecting approximately 70% of novel medications [38]. Drug candidates with poor solubility often lead to drug development failures because they have low bioavailability and poor absorption [39]. This limited water solubility of active pharmaceutical ingredients constrains their pharmacological efficacy and reduces drug absorption [40]. Various technologies are available to improve solubility, such as reducing particle size, creating solid dispersions, and using lipid-based systems [41]. Effective pharmaceutical formulation aims to address these solubility limitations early in development to improve clinical outcomes [39].

7.2. Stability & Shelf-Life Issues

Stability studies play a crucial role in determining how a drug product's quality changes over time when exposed to temperature, humidity, and light [42]. A drug product may degrade over time to a point where it becomes ineffective or unsafe due to the formation of impurities with unknown toxicity [42]. Light, humidity, and temperature changes can wreak havoc on pharmaceutical products, with potentially dangerous results [42]. Stability testing is essential during drug development to ensure that marketed products remain safe and effective under different conditions [42].

7.3. Regioselectivity in Multi-Step Synthesis

Key challenges in multistep continuous flow synthesis include controlling regioselectivity and preventing formation of undesired isomers [43,44]. Factors such as lipophilicity, solvation, and crystal lattice strength regulate solubility and can be modified to enhance it [43,44]. Enhancements in solubility can be achieved by increasing solvent affinity or decreasing lattice energy and lipophilicity [43,44].

7.4. Scale-Up Challenges

Scale-up and scale-out complexities in multiphase systems are persistent challenges in pharmaceutical formulation and development [45]. The formulation design can significantly affect the oral bioavailability of poorly soluble drugs[46].

7.5. Excipient Incompatibility with APIs

Excipients come with inherent limitations that pose challenges in drug development, manufacturing, and patient safety [47]. The limited water solubility of active pharmaceutical ingredients constrains their pharmacological efficacy [47].

7.6. Pediatric Formulation Challenges

Poor aqueous solubility, common among many new drug candidates, can lead to inconsistent absorption, necessitating higher doses and complex formulations [48].

7.7. Environmental & Sustainability Concerns

Emerging platforms supported by AI-enabled predictive modeling are promising toward realizing strong patient-centric solutions for poorly water-soluble therapeutics [49].

8. FUTURE PERSPECTIVES        

The development of nitrogen heterocycles in medicinal chemistry is rapidly evolving with the integration of artificial intelligence and machine learning in drug design, which enables faster identification of novel bioactive scaffolds and reduces the time required for lead optimization [50,51]. Advanced computational methods, including chemo genomics, metabolomics, and proteomics, are increasingly being employed to predict drug–target interactions and optimize the pharmacokinetic profiles of heterocyclic compounds [52]. Sustainable and green synthetic approaches, such as solvent-free reactions, microwave-assisted synthesis, and biocatalysis, are expected to become standard practices to reduce the environmental impact of nitrogen heterocycle production in pharmaceutical industries [53]. Emerging therapeutic modalities like PROTACs (proteolysis-targeting chimeras), antibody–drug conjugates, and molecular glues, many of which contain nitrogen heterocycles, are opening new avenues for precision medicine and targeted therapies in cancer and neurodegenerative diseases [54]. Unanswered biological questions and incomplete understanding of structure–activity relationships for many heterocyclic classes suggest that further research is essential to fully exploit their pharmaceutical potential [55].

CONCLUSION

Nitrogen heterocycles have firmly established themselves as privileged scaffolds across medicinal chemistry, agrochemicals, materials science, and catalysis, owing to their structural diversity, tunable physicochemical properties, and strong propensity for specific interactions with biological targets and functional environments [5,13,26]. The survey of classical and modern synthetic strategies—from named cyclocondensation and multicomponent reactions to transition‑metal‑catalyzed C–N bond formations, C–H activation, and green microwave‑assisted or solvent‑free protocols—demonstrates that access to structurally diverse nitrogen heterocycles is now more efficient, sustainable, and compatible with industrial requirements than ever before [53,56]. Their broad spectrum of pharmacological activities, including antimicrobial, anticancer, antiviral, analgesic, anti‑inflammatory, CNS, and enzyme‑inhibitory effects, reflects the ability of nitrogen heterocycles to mimic endogenous nucleobases and cofactors, participate in hydrogen bonding and π‑stacking, and fine‑tune binding at enzymes, receptors, and nucleic acids [17,26]. Parallel advances in fluorinated heterocycles, fragment‑based design, and nano-carrier-conjugated heterocyclic systems are accelerating the discovery of targeted and personalized therapies with improved selectivity, bioavailability, and safety profiles [5,26]. Looking ahead, deeper understanding of structure–activity relationships, wider adoption of AI‑driven design and predictive modeling, and continued development of greener synthetic methodologies are expected to unlock new nitrogen‑heterocyclic chemotypes and applications, reinforcing their central role in next‑generation drug discovery and functional material design [17,56].

REFERENCES

1. Jampilek J. Heterocycles in Medicinal Chemistry III. Molecules [Internet]. 2026 Feb 14;31(4):661. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12943221
2. Heterocyclic Compound - an overview | ScienceDirect Topics [Internet]. www.sciencedirect.com.Available from: https://www.sciencedirect.com/topics/chemistry/heterocyclic-compound
3. Clark J. Heterocyclic Chemistry Heterocyclic Chemistry [Internet].
4. Buntrock RE. Review of Heterocyclic Chemistry, 5th Edition. Journal of Chemical Education. 2012 Sep 14;89(11):1349–50.
5. Heravi MM, Zadsirjan V. Prescribed drugs containing nitrogen heterocycles: an overview. RSC Advances. 2020;10(72):44247–311.
6. Alvarez M. Iss 1 Citation: Mateo Alvarez, Significance of Heterocyclic Compounds in Modern Organic Chemistry. Organic Chemistry: An Indian Journal Editorial | [Internet]. 2024 [cited 2026 May 25];18(1):46.
7. Importance Of Heterocyclic Compounds In Modern Chemistry [Internet]. LIFECHEM PHARMA. 2026 [cited 2026 May 25]. Available from: https://www.lifechempharma.com/why-heterocyclic-compounds-are-essential-in-modern-chemistry/ 
8. Kabir E, Uzzaman M. A review on biological and medicinal impact of heterocyclic compounds. Results in Chemistry. 2022 Jan;4:100606.
9. Marshall CM, Federice JG, Bell CN, Cox PB, Njardarson JT. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023). Journal of medicinal chemistry. 2024 Jul 12;67(14).
10. Ullah F, Ullah S, Khan MFA, Mustaqeem M, Paracha RN, Rehman MF ur, et al. Fluorescent and Phosphorescent Nitrogen-Containing Heterocycles and Crown Ethers: Biological and Pharmaceutical Applications. Molecules. 2022 Oct 6;27(19):6631.
11. María-Camila Ríos, Bravo NF, Christian-Camilo Sánchez, Portilla J. Chemosensors based on N-heterocyclic dyes: advances in sensing highly toxic ions such as CN⁻ and Hg²⁺. RSC Advances. 2021 Jan 1;11(54):34206–34.
12. Boon Chong Lee, Liu CF, Qi L, Kang Zheng Yap, Song N, Min H, et al. N-Heterocyclic carbenes as privileged ligands for nickel-catalysed alkene functionalisation. Chemical Society Reviews. 2023 Jan 1;52(9):2946–91.
13. Frank É, Szőllősi G. Nitrogen-Containing Heterocycles as Significant Molecular Scaffolds for Medicinal and Other Applications. Molecules. 2021 Jul 30;26(15):4617.
14. Rusu A, Moga I, Uncu L, Hancu G. The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy. Pharmaceutics. 2023 Oct 29;15(11):2554–4.
15. MoldoveanuS, David V. Modern sample preparation for chromatography. Amsterdam, The Netherlands ; Cambridge, Ma: Elsevier; 2021.
16. Shiri P, Roosta A, Ramezanpour S, Amani AM. Editorial: Six-membered heterocycles: their synthesis and bio applications. Frontiers in Chemistry. 2023 Jun 8;11.
17. Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. Molecules. 2020 Apr 20;25(8):1909.
18. Cosgrove B, Down K, Bertrand S, Tomkinson NCO, Barker MD. Investigating the effects of the core nitrogen atom configuration on the thermodynamic solubility of 6,5-bicyclic heterocycles. Bioorganic & Medicinal Chemistry Letters [Internet]. 2020 Dec 29;33:127752.
19. Wieczorkiewicz PA, Krygowski TM, Szatylowicz H. Substituent effects and electron delocalization in five-membered N-heterocycles. Physical chemistry chemical physics : PCCP. 2024 Jan 1;26(28):19398–410.
20. Avula Balakrishna, Antonio Pedro Aguiar, Pedro, Mohmmad Younus Wani, Silva JA, Abilio J.F.N. Sobral. Paal–Knorr synthesis of pyrroles: from conventional to green synthesis. 2018 Oct 19;61(1):84–110.
21. Zhang X, Bi W, Cao Z, Shen J, Chen B. Recent Developments in the Metal-Catalyzed Synthesis of Nitrogenous Heterocyclic Compounds. Molecules (Basel, Switzerland). 2024 Nov 19;29(22):5458.
22. Zhang G, Yang B, Yang J, Zhang J. Pd-Catalyzed Asymmetric Larock Indole Synthesis to Access Axially Chiral N-Arylindoles. Journal of the American Chemical Society. 2024 Feb 13;146(8):5493–501.
23. Mohlala RL, Rashamuse TJ, Coyanis EM. Highlighting multicomponent reactions as an efficient and facile alternative route in the chemical synthesis of organic-based molecules: a tremendous growth in the past 5 years. Frontiers in chemistry. 2024 Sep 18;12:1469677.
24. Sajini T, Joseph J. Microwave-assisted synthesis of nanomaterials: a green chemistry perspective and sustainability assessment. RSC Sustainability. 2025 Jan 1;3(11):4911–35.
25. Dinodia M. N-heterocycles: Recent Advances in Biological Applications. Mini-Reviews in Organic Chemistry. 2023 Nov 1;20(7):735–47.
26. Amin A, Qadir T, Sharma PK, Jeelani I, Abe H. A Review on The Medicinal And Industrial Applications of N-Containing Heterocycles. The Open Medicinal Chemistry Journal. 2022 Nov 16;16(1)
27. Spencer AC, Panda SS. DNA Gyrase as a Target for Quinolones. Biomedicines. 2023 Jan 27;11(2):371.
28. Fukuda D, Powell D, Mulgirigama A, Vojtek I, Ozeki H, Yoshimoto D, et al. Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future. The Journal of antimicrobial chemotherapy. 2026 Feb 2;81(3)
29. Marzi M, Farjam M, Kazeminejad Z, Shiroudi A, Kouhpayeh A, Zarenezhad E. A Recent Overview of 1,2,3-Triazole-Containing Hybrids as Novel Antifungal Agents: Focusing on Synthesis, Mechanism of Action, and Structure-Activity Relationship (SAR). Journal of Chemistry. 2022 Jan 6; 2022:1–50.
30. Chhina MS, Gulati P, Singh P, Singh S, Khanna A. Oxygen & nitrogen containing heterocyclic compounds: a boon for antineoplastic research. International Journal of Pharmaceutical Sciences and Research. 2025 Dec 1;16(12).
31. Diasio RB, Offer SM. Pyrimidine and Purine Antimetabolites. Holland‐Frei Cancer Medicine. 2022 Oct 21;1–13
32. Singh Chauhan A, Ghildiyal P, Yadav S. Artificial Intelligence for Drug Discovery and Development. asp books; 2025 Apr
33. Pibiri I. Recent Advances: Heterocycles in Drugs and Drug Discovery. International journal of molecular sciences. 2024 Aug 31;25(17):9503
34. Singh M, Kaifl M, Akthar MN, Gupta N, Sagar P. Role of Heterocycles in Drug Discovery: An Overview. World Journal of Advanced Research and Reviews. 2025 Oct 31;28(1):1924–8
35. Hahn P. Role of Heterocyclic Compounds in Drug Development: An Overview. Research & Reviews: Journal of Medicinal and Organic Chemistry JOMC| [Internet]. 2024;11(8).
36. Taylor AP, Robinson RP, Fobian YM, Blakemore DC, Jones LH, Fadeyi O. Modern advances in heterocyclic chemistry in drug discovery. Organic & Biomolecular Chemistry. 2016 Jan 1;14(28):6611–37.
37. Moore D. Drug Stability: Factors Affecting Shelf Life and Methods for Evaluation. Journal of Pharmaceutics & Drug Delivery Research [Internet]. 2023;2023. 
38. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. International Journal of Pharmaceutics. 2011 Aug 30;420(1):1–10.
39. Leister D. Why Most Modern Drug Candidates Fail at Solubility [Internet]. Behind the Bench. Thermo Fisher Scientific; 2026.
40. Ascendia Pharmaceutical Solutions. 4 Factors Affecting Solubility of Drugs | Ascendia Pharmaceuticals [Internet]. Ascendiacdmo.com. Ascendia Pharmaceuticals; 2021
41. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines. 2022 Aug 23;10(9):2055.
42. Ammann C. Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products. AAPS PharmSciTech. 2011 Sep 27;12(4):1264–75.
43. He Z, Yang W, Yang F, Zhang J, Ma L. Innovative medicinal chemistry strategies for enhancing drug solubility. European Journal of Medicinal Chemistry. 2024 Sep 6;279:116842.
44. Chen J, Zou Y, Liao L, Yang B, Xing D, Zhou J, et al. Trends and Challenges in Multistep Continuous Flow Synthesis. JACS Au. 2026 Feb 3;6(2):731–55
45. Hosseini S. Current Advances and Challenges in Pharmaceutical Formulation Development and Manufacturing: A Comprehensive Review for Industry Applications. International Journal of Biomedical Science and Engineering. 2026 Mar 4;14(1):33–41.
46. Lal A. Innovative methods to increase the oral bioavailability of medications [Internet]. [cited 2026 Jun 11]
47. Deshmukh DP, Nimkar S, Phuse A, Ruikar D, Bonde D. A Systemic Review on Techniques of Solubility Enhancement for Poor Water-Soluble Drugs. Asian Journal of Pharmaceutical Research and Development. 2024 Jun 15;12(3):247–56
48. Mukta Jagtap. Recent Trends in Solubility Enhancement Techniques for Poorly Water-Soluble Drugs. Zenodo [Internet]. 2025 Nov 8 [cited 2026 Feb 11]
49. Chandramohan K, Nepolean R, Karthikeyan K, Anbarasu D, Jayaram N. Strategies for Improving Solubility and Dissolution of Poorly Water-Soluble Drugs: Current Developments and Pharmaceutical Applications. Prima Scientific. 2026 Mar 02;7(3):248. DOI: 10.56831/PSSRP-07-248
50. Shaikh, H. (2023). Use of Artificial Intelligence in Drug Discovery and its Application in Drug Development. Asian Journal of Research in Chemistry, 16(1), 83–90. DOI: 10.52711/0974-4150.2023.00014
51. Halder, A., et al. (2020). A Review on Recent Advances in Nitrogen-Containing Molecules and Biologically Active Drugs. PMC Journals, NIH, PMC7221918
52. Dong Y, Dai J, Zou Y, Rajalakshmi K, Kiruthiga N, Balaji P, et al. Strategic applications of heterocyclic compounds in pharmaceutical innovation: a business perspective. Frontiers in Chemistry. 2026 Jan 1;14(1).
53. Jassas RS, Ullah MU, Naeem N, Al-Rooqi MM, Sadiq A, Moussa Z, Ahmed SA, et al. (2022). Pharmacological significance of nitrogen-containing five and six-membered heterocyclic scaffolds as potent cholinesterase inhibitors for drug discovery. Applied Microbiology and Biotechnology, 13(10), 1359511322002136.
54. Ward M, O’Boyle NM. Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014-2023). RSC medicinal chemistry. 2025 Jan 1;16(10):4540–70
55. Martinez A, Gil C. Chapter 9. Heterocycles Containing Nitrogen and Sulfur as Potent Biologically Active Scaffolds. In royal society of chemistry; 2015. p. 231–61.
56. Sivaraj N, Sakthivel K, Kikushima K, Kostić MD, Dohi T, Singh FV. Recent advances in non-conventional synthesis of N-heterocyclic compounds: emerging strategies and biological perspectives. RSC Advances. 2025 Jan 1;15(42):35509–31